KACTUS has developed a GMP-grade universal nuclease – MaxNuclease™, which degrades all DNA and RNA into 2-5 base oligonucleotides.
KACTUS: Endonuclease – MaxNuclease™ GMP-Grade
KACTUS: CRISPR Cas9 Protein
At KACTUS, they have developed a highly-active, wild-type Cas9 nuclease based on their SAMS™ technology platform.
KACTUS: AccuBase® Base Editor
AccuBase® is a cytosine base editor that converts a C-G base pair into a T-A base pair in the genome. Designed by Base Therapeutics, manufactured by KACTUS.
KACTUS: CAR-T Target Antigens
KACTUS has developed a series of high-quality CAR-T target protein products, covering a wide range of popular targets such as CD19, BCMA, and MSLN.
KACTUS: HLA-G & LILR Proteins
At KACTUS, they offer a comprehensive range of high-quality recombinant HLA-G and LILR proteins, to support research and development in immunology and therapeutic applications.
KACTUS: Transmembrane Proteins
KACTUS has developed two transmembrane protein display platforms: virus-like particles (VLPs) and nanodiscs.
KACTUS: Immune Checkpoint Proteins
KACTUS have developed a series of immune checkpoint proteins with various tags.
KACTUS: Cytokines & Receptors
KACTUS has developed a full portfolio of tag-free or small-tag cytokines with verified cellular-level bioactivity for various cell culture applications.
KACTUS: CD3 Heterodimers
KACTUS provides a variety of highly active CD3 proteins, including monomers, dimers, and other forms, to meet the diverse needs of researchers.
KACTUS: CD19 Proteins
KACTUS’ high-quality CD19 proteins are designed for applications such as antibody screening, CAR-T cell therapy development and affinity measurements.